2021 ASCO Virtual Annual Meeting*

Download All
June 4-8, 2021; Online at https://conferences.asco.org/am
Expert faculty review and share their insights and perspectives on key findings in lung cancer presented at the 2021 ASCO Annual Meeting.
Zofia Piotrowska, MD, MHS
Karen L. Reckamp, MD, MS

Lung Cancer

Slidesets Novel RET Inhibitor BOS172738 in RET-Altered Cancers Including RET Fusion–Positive NSCLC and RET Mutation–Positive Medullary Thyroid Cancer
Slidesets IMpower010: Phase III Trial of Adjuvant Atezolizumab vs BSC in Resected Stage IB-IIIA NSCLC After Adjuvant Chemotherapy
Slidesets PACIFIC: 5-Year Survival Outcomes With Consolidation Durvalumab vs Placebo After Concurrent CRT in Unresectable Stage III NSCLC
Slidesets KEYNOTE-799: Phase II Trial of Pembrolizumab + Concurrent CRT in Unresectable Stage IIIA-C NSCLC
Slidesets CheckMate 9LA: 2-Yr Update of First-line Nivolumab + Ipilimumab With 2 Cycles of Chemotherapy vs Chemotherapy Alone in Advanced NSCLC
Slidesets FDA Pooled Analysis: Survival Outcomes With First-line Chemo-IO vs IO Alone for Treatment of Advanced NSCLC With PD-L1 Expression 1% to 49%
Slidesets Phase II CodeBreaK100: Overall Survival and Exploratory Subgroup Analyses of Sotorasib in Pretreated KRAS p.G12C–Mutated NSCLC
Slidesets Biomarker Testing and Clinical Trial Enrollment in NSCLC: Retrospective Analysis of Racial Disparities
Slidesets CHRYSALIS Phase I Trial: Amivantamab + Lazertinib in Osimertinib-Relapsed, Chemotherapy-Naive EGFR-Mutated Advanced NSCLC, Including Analyses of Biomarkers of Response
Slidesets Phase I Study of Patritumab Deruxtecan in Patients With EGFR-Mutated NSCLC and Resistance to EGFR TKI Therapy
Slidesets CheckMate 227 Part 1: 4-Yr Update of First-line Nivolumab + Ipilimumab vs Platinum-Doublet Chemotherapy in Advanced NSCLC
Slidesets TROPION-PanTumor01: Phase I Dose Analysis of Datopotamab Deruxtecan, a Novel TROP2-Targeted ADC, in Pretreated Advanced NSCLC

Review expert perspectives on the most clinically relevant data on NSCLC presented at the 2021 ASCO Annual Meeting.

Zofia Piotrowska, MD, MHS Karen L. Reckamp, MD, MS Physicians: maximum of 1.0 AMA PRA Category 1 Credit™ Released: August 20, 2021 Expired: No longer available for credit
Provided by Clinical Care Options, LLC
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Amgen
AstraZeneca
Bristol-Myers Squibb
Daiichi Sankyo, Inc.
Ipsen Biopharmaceuticals, Inc.
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings